Skip to main content

NCT00212810 - TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study

TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Topiramate
Product Name
TOPAMAX®
Therapeutic Area
Nervous System Diseases
Enrollment
385
% Female
89.1%
% White
81.8%
Product Class
Anticonvulsants
Sponsor Protocol Number
CAPSS-381 (INTREPID)
Data Holder
Johnson & Johnson
Condition Studied
Migraine Disorders
Mean/Median Age (Years)
40.3

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
4

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.